Viewing Study NCT00665392


Ignite Creation Date: 2025-12-24 @ 3:35 PM
Ignite Modification Date: 2026-02-24 @ 3:15 PM
Study NCT ID: NCT00665392
Status: COMPLETED
Last Update Posted: 2025-08-01
First Post: 2008-04-22
Is NOT Gene Therapy: True
Has Adverse Events: True

Brief Title: Cetuximab and Combination Chemotherapy in Patients With Stage III-IV Resectable Oropharynx Cancer
Sponsor: GERCOR - Multidisciplinary Oncology Cooperative Group
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Head and Neck Cancer View
Keywords:

Keywords

Keyword Brief Keyword Text View
None stage III squamous cell carcinoma of the oropharynx View
None stage IV squamous cell carcinoma of the oropharynx View
None tongue cancer View